Skip to content

IO Safety Panel

Human iPSC-based multi-tissue safety screening for immuno-oncology programs

Safety risks in ADC and antibody programs often emerge only
after key decisions have been made. At that point, flexibility is limited.
By assessing functional toxicity across seven human tissues before
in vivo commitment, the Ncyte IO Safety Panel supports more informed
lead progression decisions.
 
Start a Conversation
HOME services io safety panel ncardia
_65A9389

Why is early IO safety screening needed?

Off-target binding and on-target off-tumour activity remain major sources of late-stage failure in immuno-oncology. Identifying these risks late compresses timelines and limits mitigation options.

Early, multi-tissue screening provides context. It helps teams understand where functional toxicity emerges and which signals require follow-up before committing to late tox.

iPSC-derived systems support this by reducing donor variability and enabling reproducible comparisons across tissues.

Seven human tissues in a single workflow

The Ncyte IO Safety Panel evaluates cytotoxic risk across seven healthy human tissues within one standardized experimental workflow:

  • Motor Neurons
    Neurons 
  • vCM
    Cardiomyocytes
  • Endothelial_3
    Endothelial cells
  • Melanocytes
    Melanocytes
  • Hepatocytes
    Hepatocytes
  • Intestinal epithelial cells
    Intestinal epithelial cells
  • lung cells
    Alveolar epithelial cells

All tissues are fully iPSC-derived and manufactured under controlled conditions, enabling direct comparison of tissue sensitivity and efficient identification of liabilities.

nc_io panel

Functional readouts and biological content

Real-time impedance monitoring captures functional responses over time, including onset and progression that endpoint assays miss.

Immunocytochemistry or immunofluorescence confirms target expression and cellular context, supporting biological interpretation of functional effects. For example, early impedance changes in neuronal models can indicate rapid functional compromise.

IND-oriented reporting 

Results are delivered in a structured, regulatory-oriented report suitable for internal governance and IND briefing materials.

This approach has supported IND activities for TCR-based programs and is now available for ADCs and antibodies.

Typical report elements include:

    • Study overview and tissue-level interpretation
    • Methods and assay conditions
    • Time-resolved impedance data and key figures
    • ICC or IF image panels with marker context
    • Structured tables and appendices for documentation
nc_material (7)

ON-DEMAND WEBINAR: Learn more about functional IO safety screening for lead validation

Partner With the Proven iPSC Experts

Explore human-relevant IO safety for your lead candidates

Start a Conversation